Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX -0.40%21 PE Ratio (TTM) is 30.75 as of Aug. 05, 2026, which is 1% below its 10-year median of 31.01. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 640 Drug Manufacturers companies, Influx Healthtech ranks worse than 65.78% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-05), Influx Healthtech's share price is
₹287.50.
Influx Healthtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9.35. Therefore, Influx Healthtech's PE Ratio (TTM) for today is 30.75.
The historical rank and industry rank for Influx Healthtech's PE Ratio (TTM) or its related term are showing as below:
NSE:INFLUX'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 22.75 Med: 31.01 Max: 41.03
Current: 33
During the past 5 years, the highest PE Ratio (TTM) of Influx Healthtech was 41.03. The lowest was 22.75. And the median was 31.01.
NSE:INFLUX's PE Ratio (TTM) is ranked worse than 65.78% of 640
companies
in the Drug Manufacturers industry
Industry Median: 20.76
vs NSE:INFLUX: 33.00
During the past 5 years, Influx Healthtech's highest 3-Year average EPS without NRI Growth Rate was 44.30% per year. The lowest was 43.80% per year. And the median was 44.05% per year.
Influx Healthtech's EPS (Basic) for the
six
months ended in Mar. 2026 was ₹4.54.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9.35.
Influx Healthtech (NSE:INFLUX) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Influx Healthtech PE Ratio (TTM) Related Terms
Influx Healthtech PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Influx Healthtech's Share Price of today is ₹287.50.
For company reported semi-annually, Influx Healthtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹9.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Influx Healthtech (NSE:INFLUX) has a PE Ratio (TTM) of 30.75 as of Aug. 05, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Influx Healthtech and its competitors. This is near median its historical median of 31.01. Over the past decade, Influx Healthtech's PE Ratio (TTM) has ranged from 22.75 to 41.03. According to the industry distribution chart, Influx Healthtech ranks #421 out of 640 companies in the Drug Manufacturers industry, placing it in the top 65.8%.
Is Influx Healthtech's PE Ratio (TTM) too high?
Influx Healthtech's current PE Ratio (TTM) of 30.75 is near median its 10-year median of 31.01. Over the past 10 years, this metric has ranged from a low of 22.75 to a high of 41.03. The Drug Manufacturers industry median PE Ratio (TTM) is 20.76. Influx Healthtech's value of 30.75 is 48.1% above this industry median. Based on the distribution chart, Influx Healthtech ranks #421 out of 640 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's PE Ratio (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #421 out of 640 companies for PE Ratio (TTM). This places Influx Healthtech in the lower half of its industry. The industry median PE Ratio (TTM) is 20.76. Influx Healthtech's value of 30.75 is 48.1% above this benchmark. Historically, Influx Healthtech's own PE Ratio (TTM) has ranged from 22.75 to 41.03 over the past decade. While the company's 10-year median is 31.01 vs. the industry median of 20.76, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.76, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current PE Ratio (TTM) of 30.75 is 48.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current PE Ratio (TTM) is 30.75, which is near median its own 10-year median of 31.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current PE Ratio (TTM) of 30.75. The current PE Ratio (TTM) is 30.75, which is near median its 10-year median of 31.01 and 48.1% above the Drug Manufacturers industry median of 20.76. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current PE Ratio (TTM) is 30.75 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
